The National Institutes of Health (NIH) called an early halt to one arm of a study on the advice of an independent data and safety monitoring board after finding that people with kidney disease and protein in their urine were more likely to postpone kidney failure using either an ACE inhibitor or a beta blocker than a calcium channel blocker (CCB).
The FDA has approved Novantrone (mitoxantrone), an approved cancer drug, for treating patients with advanced or chronic Multiple Sclerosis (MS), a disease that attacks the nervous system and can cause weakness, impaired vision, loss of balance, and poor muscle coordination. MS can have different patterns, sometimes leaving patients relatively well after episodes of acute worsening, sometimes leading to progressive disability that persists after episodes of worsening. In the worst cases the disease can lead to paralysis.
Two randomized multi-center clinical studies, totaling about 200 patients, demonstrated that Novantrone could reduce the number of relapse
episodes and decrease the progression of disability in patients with
secondary (chronic) progressive, progressive relapsing, or worsening
relapsing-remitting MS (all forms of the disease in which patients become
significantly more abnormal between relapses as time passes). Get the prescribing information you need in today's Vidyya.
The Food and Drug Administration (FDA) is announcing two decisions on health claims that were the subject of a court decision. One proposed claim that stated 0.8 mg of folic acid in a dietary supplement was more effective in reducing the risk of neural tube defects than a lower amount in foods was not authorized. The second proposed health claim about dietary fiber and reduced risk of colrectal cancer could not be substantiated.
Diabetics should be among the
first in line to receive their flu shots this year, putting special importance
on it because of the delay in the availability of the shots. The U.S. Centers
for Disease Control and Prevention (CDC) recommends vaccination for those aged
50 and older and people with diabetes, among other chronic diseases.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.